GLP-1 Agonists Market 2034: 7MM Insights, 6+ Active Companies, 5 Key Pipeline Drugs, and Clinical Progress, states DelveInsight

DelveInsight's latest GLP-1 Agonists Market Insights Report provides a in-depth and forward-looking analysis of one of the most dynamic therapeutic classes shaping the future of metabolic disorder management. With expanding clinical trial activity, evolving regulatory pathways across the FDA, EMA, and PMDA, and a strong pipeline of next-generation candidates, GLP-1 agonists are redefining treatment approaches for type 2 diabetes, obesity, and other cardiometabolic conditions across the seven major markets (7MM).

The report delivers a comprehensive understanding of current treatment practices, emerging GLP-1 agonist therapies, mechanism of action (MOA), route of administration (ROA), target patient populations, and competitive intelligence, offering valuable insights for pharmaceutical companies, investors, healthcare stakeholders, and decision-makers navigating this rapidly evolving space.

Discover which therapies are expected to grab the GLP-1 agonists market share @ GLP-1 Agonists Market Report - https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

A Rapidly Evolving GLP-1 Agonists Therapeutic Landscape
GLP-1 agonists have gained significant traction due to their multifaceted clinical benefits, including glucose-dependent insulin secretion, appetite regulation, and favorable metabolic effects. These therapies mimic the activity of glucagon-like peptide-1, a naturally occurring hormone that plays a central role in glycemic control and energy balance. As a result, GLP-1 agonists have become integral to modern type 2 diabetes management and are increasingly explored for broader metabolic indications.

DelveInsight's analysis highlights how continuous innovation in drug design, delivery formats, and dosing regimens is transforming patient adherence and treatment outcomes. The shift from injectable formulations toward oral GLP-1 agonists represents a critical advancement, expanding accessibility and patient preference while reshaping prescribing patterns across global markets.

GLP-1 agonists Market Insights Across the 7MM
The GLP-1 agonists market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, providing a granular evaluation of regional treatment practices and development trends from 2020 to 2034. The report examines how evolving regulatory frameworks, healthcare guidelines, and reimbursement considerations influence the adoption of GLP-1 therapies across these geographies.

According to DelveInsight, the GLP-1 agonists market is anticipated to grow at a notable CAGR through 2034, supported by increasing clinical adoption, expanding indications, and a robust pipeline of emerging candidates. The emphasis on personalized medicine and patient-centric care continues to drive interest in therapies offering improved efficacy, convenience, and safety profiles.
Learn more about the FDA-approved GLP-1 agonists @ GLP-1 Agonists Drugs - https://www.delveinsight.com/report-store/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Competitive Landscape: Key GLP-1 Agonists Companies
The competitive landscape for GLP-1 agonists is marked by strong participation from both established pharmaceutical leaders and emerging biotech innovators. Key companies actively developing GLP-1 agonists include:
• Novo Nordisk A/S
• Veru Inc.
• Viking Therapeutics, Inc.
• Terns Pharmaceuticals, Inc.
• Eccogene
• AstraZeneca, among others
These companies are focused on advancing differentiated GLP-1 agonists that leverage novel mechanisms, dual-receptor targeting, and oral delivery technologies to address unmet needs in metabolic disease treatment.

Key GLP-1 Agonist Therapies in Development
Several GLP-1 agonist candidates are drawing attention due to their innovative profiles and ongoing clinical development:
• Saxenda (Novo Nordisk A/S) - A well-recognized GLP-1 agonist with applications extending beyond glycemic control.
• Enobosarm (Veru Inc.) - Investigated for its role in metabolic health.
• VK2735 (Viking Therapeutics, Inc.) - A dual GLP-1/GIP receptor agonist designed to address obesity and related metabolic disorders.
• TERN-601 (Terns Pharmaceuticals, Inc.) - An oral small-molecule GLP-1 receptor agonist targeting obesity.
• ECC5004 (Eccogene/AstraZeneca) - A once-daily oral GLP-1 receptor agonist under investigation for cardiometabolic conditions.
These therapies represent a new generation of GLP-1 agonists aimed at improving treatment flexibility, patient compliance, and clinical outcomes.

To know more about GLP-1 agonists clinical trials, visit @ GLP-1 Agonists Treatment Drugs - https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Recent Clinical and Strategic Developments
The GLP-1 agonists pipeline has witnessed several notable developments:
• Several GLP-1 receptor agonists have received regulatory approval, including TRULICITY (dulaglutide), BYETTA and BYDUREON (exenatide), VICTOZA (liraglutide), OZEMPIC, WEGOVY, and RYBELSUS (semaglutide), as well as MOUNJARO and ZEPBOUND (tirzepatide), among others.
• In August 2025, Novo Nordisk disclosed that the FDA approved WEGOVY as the first GLP-1 receptor agonist indicated for adults with Metabolic Dysfunction-associated Steatohepatitis (MASH) and moderate-to-advanced fibrosis, excluding cirrhosis, when used alongside diet and physical activity. This decision was supported by evidence showing meaningful improvements in both MASH and fibrosis, with a confirmatory trial currently in progress.
• In June 2025, MBX Biosciences announced the submission of an Investigational New Drug (IND) application to the FDA for MBX 4291, a long-acting GLP-1/GIP receptor dual agonist prodrug developed for obesity. The IND received clearance in July, and the company expects to initiate a Phase I clinical study in the third quarter of 2025.
• In April 2025, Northstrive Biosciences reported receiving initial guidance from the FDA following its planned Type B pre-IND meeting, endorsing the progression of its EL-22 program-designed for use in combination with GLP-1 receptor agonists-toward a Phase II clinical trial.
• March 2024: Viking Therapeutics, Inc. reported encouraging results from a Phase I multiple-dose clinical trial of oral VK2735, a dual GLP-1/GIP receptor agonist aimed at addressing obesity.
• March 2024: Arecor Therapeutics plc, in collaboration with TRx Biosciences Limited, announced a joint research and development initiative focused on creating an oral GLP-1 receptor agonist formulation.
• November 2023: Terns Pharmaceuticals, Inc. initiated dosing of the first participant in the Phase 1 clinical trial of TERN-601, its oral small-molecule GLP-1 receptor agonist for obesity.
• November 2023: AstraZeneca and Eccogene entered into an exclusive agreement for ECC5004, an oral once-daily GLP-1 receptor agonist being evaluated for obesity, type 2 diabetes, and other cardiometabolic conditions.
These developments underscore the industry's strong commitment to advancing oral GLP-1 therapies and expanding the therapeutic potential of this drug class.

GLP-1 agonists Regulatory and Treatment Landscape
Several GLP-1 agonists have already received FDA approval for the treatment of type 2 diabetes, including exenatide, liraglutide, dulaglutide, semaglutide, and lixisenatide. A key milestone occurred in 2019, when the FDA approved Rybelsus (oral semaglutide) as the first oral GLP-1 treatment for type 2 diabetes, offering patients an alternative to injectable therapies.

Beyond diabetes, GLP-1 agonists are increasingly explored for obesity and other metabolic conditions due to their effects on appetite suppression, gastric emptying, and energy regulation. Their expanding clinical utility continues to position GLP-1 agonists as cornerstone therapies in metabolic disease management.

Download free sample report @ https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

GLP-1 agonists Epidemiology and Patient Population Insights
The GLP-1 agonists market report incorporates a detailed epidemiological assessment, evaluating historical, current, and forecasted patient populations across the 7MM from 2020 to 2034. The analysis is segmented by:
• Total cases by indication
• Treatable cases by indication
These insights help stakeholders understand patient trends, treatment eligibility, and long-term demand dynamics for GLP-1 therapies across major markets.

Discover more about GLP-1 agonists drugs in development @ GLP-1 Agonists Clinical Trials - https://www.delveinsight.com/sample-request/glucagon-like-peptide1-glp1-agonists-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope and Strategic Value of the GLP-1 Agonists Market Report
DelveInsight's GLP-1 Agonists Market Report delivers extensive coverage, including:
• Study Period: 2020-2034
• GLP-1 Agonists Report Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key GLP-1 Agonists Companies: Novo Nordisk A/S, Veru Inc., Viking Therapeutics, Inc., Terns Pharmaceuticals, Inc., Eccogene, AstraZeneca, and others
• Key GLP-1 Agonists Drugs: Saxenda, Enobosarm, VK2735, TERN-601, and ECC5004, among others
• Market outlook and dynamics
• Competitive intelligence and SWOT analysis
• Market entry strategies
• Unmet needs and KOL perspectives
• Analyst insights on current and emerging therapies
• Market access and reimbursement considerations
By combining clinical, regulatory, epidemiological, and competitive insights, the report equips stakeholders with actionable intelligence to support strategic planning, product development, and investment decisions.

Looking Ahead
As research accelerates and oral GLP-1 agonists gain momentum, the GLP-1 agonists market is poised to remain at the forefront of metabolic disease innovation through 2034. Continued advancements in MOA, ROA, and clinical differentiation are expected to redefine standards of care and unlock new opportunities across global healthcare systems.

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.